---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-124500"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2025-12-29T23:59:59+00:00"
generated_at: "2026-05-16T12:11:42.011348+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Acura Pharmaceuticals extends debt maturity, secures additional loans from AD Pharma, warns of possible shutdown

## Summary
- Received $300k in three new loans from Abuse Deterrent Pharma, raising principal to $9,294,279 at 5.25% interest.
- Amended license agreement for LTX-03, extending FDA NDA acceptance deadline from Dec 31, 2025 to June 30, 2026.
- Extended maturity of secured promissory note and warrant expiration to June 30, 2026.
- AD Pharma now directly owns approximately 65% of Acura's outstanding common stock.
- Company warns it may scale back operations or seek bankruptcy protection if additional financing is not obtained by end of December 2025.

## SEC filing metadata
- accession: 0001104659-25-124500
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2025-12-29T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/tm2534375d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-124500
- JSON: https://secwatch.observer/filing/0001104659-25-124500.json
- Plain text: https://secwatch.observer/filing/0001104659-25-124500.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $100,000 loans with Abuse Deterrent Pharma, LLC at 5.25%.
  - Instrument: loan
  - Principal: $100,000 loans
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Event: incurrence
  source text: On each of November 12, 2025, November 21, 2025 and December 12, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm
- Debt Financings
  ACURA PHARMACEUTICALS, INC amended debt with Abuse Deterrent Pharma, LLC maturing June 30, 2026.
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Maturity: June 30, 2026
  - Event: amendment
  source text: This amendment #7 has an effective date of December 22, 2025 and changes the maturity date of the Amended Note from December 31, 2025 to June 30, 2026, at which time all principal and interest is due.
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm
- Material Agreements
  ACURA PHARMACEUTICALS, INC entered into Note with Abuse Deterrent Pharma, LLC (AD Pharma) valued at $100,000 loans (effective 2025-11-12).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Abuse Deterrent Pharma, LLC (AD Pharma)
  - Value: $100,000 loans
  - Effective: 2025-11-12
  source text: On each of November 12, 2025, November 21, 2025 and December 12, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm
- Material Agreements
  ACURA PHARMACEUTICALS, INC amended Amended Agreement with AD Pharma (effective 2025-12-22).
  - Action: amendment
  - Agreement: license
  - Counterparty: AD Pharma
  - Effective: 2025-12-22
  source text: This amendment #13 has an effective date of December 22, 2025 and extends the FDA’s acceptance date of a New Drug Application (“NDA”) for LTX-03 from December 31, 2025 to June 30, 2026 (“NDA Acceptance Date”) (“Amended Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm
- Material Agreements
  ACURA PHARMACEUTICALS, INC amended Warrant with AD Pharma (effective 2025-12-22).
  - Action: amendment
  - Counterparty: AD Pharma
  - Effective: 2025-12-22
  source text: nd December 12, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm
- Material Agreements
  ACURA PHARMACEUTICALS, INC amended Amended Note with AD Pharma (effective 2025-12-22).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: AD Pharma
  - Effective: 2025-12-22
  source text: This amendment #7 has an effective date of December 22, 2025 and changes the maturity date of the Amended Note from December 31, 2025 to June 30, 2026, at which time all principal and interest is due.
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925124500/0001104659-25-124500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.